GGrantIndex
Sort

30,917 grants matching tumor microenvironment

ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway

$474,416
Wafik S El-Deiry · Brown University · R01 · FY2022 · CA

ONC201/TIC10 Anti-tumor Effect Through Regulation of the TRAIL pathway

$474,416
Wafik S El-Deiry · Brown University · R01 · FY2023 · CA

The Role of Lumican in the cornea

$474,342
Shukti Chakravarti · Johns Hopkins University · R56 · FY2007 · EY

Targeting lymph node metastases to block cancer progression

$474,295
Timothy P Padera · Massachusetts General Hospital · R01 · FY2024 · CA

Modulation of Tumor Microenvironment by Microbiome in Head and Neck Cancer

$474,275
Shi-Long Lu · University Of Colorado Denver · R56 · FY2019 · DE

Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases

$474,214
David R Rowley · Baylor College Of Medicine · R01 · FY2019 · CA

CD19 Directed CAR Therapy

$474,213
Carl H. June · University Of Pennsylvania · R01 · FY2013 · CA

Leader cell development and function in Breast Tumor Collective Migration

$474,135
Gregory Longmore · Washington University · R01 · FY2024 · CA

Neoadjuvant immunotherapy approaches to early stage melanoma

$474,126
Meenhard Herlyn · Wistar Institute · P50 · FY2025 · CA

Intrapleural immunotherapeutic nanoparticles for MPE treatment

$473,950
Dawen Zhao · Wake Forest University Health Sciences · R01 · FY2021 · CA

Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody

$473,941
Paul Mathew · Tufts Medical Center · R01 · FY2021 · CA

Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody

$473,941
Paul Mathew · Tufts Medical Center · R01 · FY2020 · CA

Project 3: Transcriptomic subtypes, response predictions, and therapy selection

$473,937
Jen Jen Yeh · Univ Of North Carolina Chapel Hill · P50 · FY2025 · CA

Determinants of immunotherapy response in NASH-Hepatocellular carcinoma

$473,881
Josep M Llovet · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA

Computational Methods for Identifying Non-coding Cancer Drivers

$473,876
Ekta Khurana · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · CA

Metabolic and molecular regulation of myeloid cell functions in brain cancer

$473,753
Filippo Veglia · Wistar Institute · R01 · FY2025 · NS

Targeting UHRF1 in combinational immunotherapy

$473,749
Xiao-Fan Wang · Duke University · R01 · FY2019 · CA

PD-1/PD-L1 modulation in cancer therapy

$473,681
Drew M. Pardoll · Johns Hopkins University · R01 · FY2019 · CA

Reversing cancer immunosuppression using attenuated Listeria monocytogenes

$473,641
Daniel A Portnoy · University Of California Berkeley · R01 · FY2024 · CA

Reversing cancer immunosuppression using attenuated Listeria monocytogenes

$473,641
Daniel A Portnoy · University Of California Berkeley · R01 · FY2025 · CA

Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling inHuman Lymphomas

$473,623
Ankur Singh · Georgia Institute Of Technology · R01 · FY2021 · CA

Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer

$473,620
Raymond B Birge · Rutgers Biomedical And Health Sciences · R01 · FY2023 · CA

Project 2: Investigating cell intrinsic and extrinsic drivers of prostate cancer bone metastasis

$473,522
Cory Abate-Shen · Columbia University Health Sciences · P01 · FY2023 · CA

Targeting a phosphatidylserine/TAM receptor/PD-L1 axis as a vulnerability in cancer

$473,506
Raymond B Birge · Rutgers Biomedical And Health Sciences · R01 · FY2025 · CA

Non-oncogene addiction in cancer cells

$473,481
Ji Luo · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA